KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Retained Earnings: 2009-2024

Historic Retained Earnings for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to -$2.2 billion.

  • Acadia Pharmaceuticals' Retained Earnings rose 11.12% to -$2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 billion, marking a year-over-year increase of 11.12%. This contributed to the annual value of -$2.2 billion for FY2024, which is 9.32% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Retained Earnings of -$2.2 billion as of FY2024, which was up 9.32% from -$2.4 billion recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Retained Earnings ranged from a high of -$2.0 billion in FY2020 and a low of -$2.4 billion during FY2023.
  • In the last 3 years, Acadia Pharmaceuticals' Retained Earnings had a median value of -$2.4 billion in 2022 and averaged -$2.3 billion.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Retained Earnings fell by 16.52% in 2020 and then grew by 9.32% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Retained Earnings (Yearly) stood at -$2.0 billion in 2020, then decreased by 8.45% to -$2.2 billion in 2021, then decreased by 10.03% to -$2.4 billion in 2022, then declined by 2.59% to -$2.4 billion in 2023, then climbed by 9.32% to -$2.2 billion in 2024.